FWIW, a couple weeks ago I was on a 4 hour flight and talk about serendipity, I was seated next to a gentleman who was a high level scientist at Pfizer. As luck would have it, his specialty is Alzheimers and he was directly involved in the Medivation deal.
We literally talked the entire flight. He was at ICAD and his job was to report to Pfizer the phase two results of Bap. He had with him his laptop and incredibly he had every slide from the presentation which we discussed at length. We also discussed the Acorda MS drug among others. There is more to this story which I was reluctant to discuss on these boards, however, I can say his report was positive as he expects Bap to reach the market by 2011 with at least 3 billion in sales down the road. He also spoke very favorably of Tysabri. For now, I will leave it at that.